LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL

Clinical trials for LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL explained in plain language.

Never miss a new study

Get alerted when new LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL trials appear

Sign up with your email to follow new studies for LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet recruiting 1

New hope for Tough-to-Treat lung cancer: trial tests Triple-Threat drug combo

Disease control Not yet recruiting

This study is testing whether a new targeted pill called zongertinib is safe and tolerable when combined with standard chemotherapy, with or without an immunotherapy drug (pembrolizumab), for people with advanced lung cancer that has a specific HER2 mutation. The main goal is to …

Matched conditions: LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL

Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated Mar 31, 2026 12:11 UTC

LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL

Get alerted when new LUNG CANCER, NON-SQUAMOUS, NON-SMALL CELL trials appear

New hope for Tough-to-Treat lung cancer: trial tests Triple-Threat drug combo